Why the study?
Does FR 168888 reduce reperfusion-induced ventricular arrhythmias and mortality in an anesthetized rat ischemia/reperfusion model?
Does FR 168888 reduce reperfusion-induced ventricular arrhythmias and mortality in an anesthetized rat ischemia/reperfusion model?
FR 168888 demonstrates antiarrhythmic efficacy against reperfusion-induced ventricular fibrillation and mortality in a rat model, even when administered after the onset of ischemia.
Answers are grounded in this paper and cite their sources.
Supports post-ischemic antiarrhythmic testing of FR 168888 in rats; leaves open translation to human reperfusion arrhythmias.
Effects of pre-ischemic and post-ischemic treatment with FR 168888 (5-hydroxymethyl-3-(pyrrol-1-yl) benzoylguanidine methanesulfonate), a Na+/H+ exchange inhibitor, on reperfusion-induced ventricular arrhythmias were examined in an ischemia/reperfusion model of anesthetized rat. FR 168888 (0.3 mg/kg) significantly reduced the incidence of ventricular fibrillation (VF) and mortality induced by reperfusion following 5-min coronary occlusion, when it was intravenously administered 5 min before coronary artery occlusion. Post-ischemic treatment with FR 168888 (0.3-10 mg/kg), i.e. given 3 min after the start of occlusion, reduced the incidence of VF and mortality. In order to examine the optimal time of administration, FR 168888 (3 mg/kg) was administered 1 or 3 min after the start of occlusion or immediately before reperfusion. There was no significant difference in the reduction of VF and mortality among the three post-ischemic treatment groups. FR 168888 (3 and 10 mg/kg) significantly increased the blood pressure during ischemia without affecting the heart rate. These results indicate that FR 168888 has antiarrhythmic effects on reperfusion-induced arrhythmias even administered after coronary occlusion.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: